SCHEMBL30196076

SCHEMBL30196076

CCOc1ncccc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 4/20 0.50
SLC6A4 P31645 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 3/20 0.47
LMNA P02545 3/20 0.47
SYK P43405 1/20 0.45
POLB P06746 1/20 0.45
GRM5 P41594 2/20 0.44
PLAU P00749 1/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
PPARG P37231 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CHRNB4 P30926 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27863637 1.00 SLC6A2 (0.50) SLC6A2SLC6A4SMN1; SMN2HPGDLMNA
SCHEMBL31078868 0.88 HPGD (0.55) SLC6A2SLC6A4SMN1; SMN2HPGDLMNA
SCHEMBL1697616 0.88 HPGD (0.55) SLC6A2SLC6A4SMN1; SMN2HPGDLMNA
SCHEMBL30196047 0.85 SMN1; SMN2 (0.43) SLC6A2SLC6A4SMN1; SMN2HPGDLMNA
SCHEMBL2700104 0.84 CHRNB4 (0.51) SLC6A2SLC6A4SMN1; SMN2HPGDLMNA
SCHEMBL29612256 0.83 CHRNB4 (0.49) SLC6A2SLC6A4SMN1; SMN2LMNASYK
SCHEMBL63365 0.83 CHRNB4 (0.49) SLC6A2SLC6A4SMN1; SMN2LMNASYK
SCHEMBL2352417 0.81 HTR1A (0.47) SLC6A2SLC6A4SMN1; SMN2LMNASYK
Hydrochloric Acid SCHEMBL5669854 0.81 CHRNB4 (0.47) SLC6A2SLC6A4SMN1; SMN2LMNASYK
SCHEMBL30196232 0.81 MAPT (0.38) SLC6A2SLC6A4SMN1; SMN2HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230148402-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2023-05-11 US disclosed
US-11559538-B2 Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors PFIZER INC. (US) 2023-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11559538-B2 Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors PDE4B, PDE4A, PDE3B SLC6A2 828/4885SLC6A4 940/4885SMN1; SMN2 841/4885
US-20230148402-A1 Boron Containing PDE4 Inhibitors PDE4B, PDE4A, PDE3B SLC6A2 708/4885SLC6A4 472/4885SMN1; SMN2 2176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.